• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1 型神经纤维瘤病外周神经鞘瘤的纵向评估:丛状神经纤维瘤和明显结节性病变的生长分析。

Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.

机构信息

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.

Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

出版信息

Neuro Oncol. 2020 Sep 29;22(9):1368-1378. doi: 10.1093/neuonc/noaa053.

DOI:10.1093/neuonc/noaa053
PMID:32152628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7523449/
Abstract

BACKGROUND

Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NF1) is critical to optimal clinical care and the development of meaningful clinical trials.

METHODS

We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196).

RESULTS

DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients' age at initial MRI (Spearman's r [95% CI]: -0.60 [-0.73, -0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman's r [95% CI]: -0.25 [-0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman's r [95% CI]: -0.52 [-0.67, -0.32] and -0.61 [-0.75, -0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively).

CONCLUSION

We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen.

摘要

背景

了解神经纤维瘤病 1 型(NF1)中非恶性周围神经鞘瘤(PNST)的自然史对于优化临床护理和开展有意义的临床试验至关重要。

方法

我们使用容积 MRI 分析,对参加自然史研究(NCT00924196)的患者进行了丛状神经纤维瘤(PNs)和具有明显结节外观的 PNST(明显结节性病变[DNL])的生长纵向分析。

结果

在 122 例患者中观察到 58 例(45.6%)有 DNL(中位数为每例患者 2 个 DNL)。在随访中发生的 DNL 中,中位发病年龄为 17 岁。在初始 MRI 时,PN 生长率与患者年龄之间观察到中度负相关(Spearman r [95%CI]:-0.60 [-0.73,-0.43],n=70),而 DNL 仅观察到弱相关(Spearman r [95%CI]:-0.25 [-0.47,0.004];n=61)。我们观察到 PN 和 DNL 的肿瘤生长率与基线肿瘤体积之间存在中度负相关(Spearman r [95%CI]:-0.52 [-0.67,-0.32]和-0.61 [-0.75,-0.42])。在 10 个 PNs 和 7 个 DNL 中观察到肿瘤体积自发减少(每年减少的中位数,分别为 3.6%和 7.3%)。

结论

我们证实了以前描述的发现,即大多数生长最快的 PNs 见于幼儿。DNL 往往在生命后期发展,其生长与年龄的关系最小。PN 和 DNL 的不同生长特征表明这些病变具有不同的生物学特性,可能需要不同的临床管理和临床试验设计。在 PNs 和 DNL 的亚组中,观察到肿瘤体积的自发缓慢消退。

相似文献

1
Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.1 型神经纤维瘤病外周神经鞘瘤的纵向评估:丛状神经纤维瘤和明显结节性病变的生长分析。
Neuro Oncol. 2020 Sep 29;22(9):1368-1378. doi: 10.1093/neuonc/noaa053.
2
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).18-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)评估 1 型神经纤维瘤病患者结节性病变伴丛状神经纤维瘤(PN)或恶性外周神经鞘瘤(MPNST)。
Pediatr Blood Cancer. 2013 Jan;60(1):59-64. doi: 10.1002/pbc.24212. Epub 2012 May 29.
3
[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.[18F]-氟代脱氧葡萄糖正电子发射断层扫描在 1 型神经纤维瘤病和丛状神经纤维瘤患儿中的应用:与恶性转化的相关性。
J Neurooncol. 2012 Jul;108(3):469-75. doi: 10.1007/s11060-012-0840-5. Epub 2012 Mar 11.
4
Association between benign and malignant peripheral nerve sheath tumors in NF1.1型神经纤维瘤病中良性与恶性周围神经鞘膜瘤的关联
Neurology. 2005 Jul 26;65(2):205-11. doi: 10.1212/01.wnl.0000168830.79997.13.
5
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.[18F]2-氟-2-脱氧-D-葡萄糖正电子发射断层扫描(FDG PET)作为1型神经纤维瘤病(NF1)相关恶性外周神经鞘瘤(MPNST)的诊断工具:一项长期临床研究
Ann Oncol. 2008 Feb;19(2):390-4. doi: 10.1093/annonc/mdm450. Epub 2007 Oct 11.
6
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.1 型神经纤维瘤病患者使用全身 MRI 进行的神经内神经纤维瘤生长行为的 10 年随访。
Neurology. 2023 Feb 14;100(7):e661-e670. doi: 10.1212/WNL.0000000000201535. Epub 2022 Nov 4.
7
Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.NF I患者中丛状和弥漫性神经纤维瘤与恶性外周神经鞘膜瘤的关联:一项全身MRI评估
Skeletal Radiol. 2024 Apr;53(4):769-777. doi: 10.1007/s00256-023-04497-z. Epub 2023 Oct 31.
8
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.18氟脱氧葡萄糖正电子发射断层扫描((18)FDG PET)在检测神经纤维瘤病1型丛状神经纤维瘤内发生的恶性外周神经鞘瘤中的应用评估
J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7. doi: 10.1136/jnnp.68.3.353.
9
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.通过容积磁共振成像测量1型神经纤维瘤病丛状神经纤维瘤的生长速率:与年龄和体重的关系
Neurology. 2007 Feb 27;68(9):643-7. doi: 10.1212/01.wnl.0000250332.89420.e6. Epub 2007 Jan 10.
10
Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.体积 MRI 分析 1 型神经纤维瘤病中的丛状神经纤维瘤:两种方法的比较。
Acad Radiol. 2018 Feb;25(2):144-152. doi: 10.1016/j.acra.2017.09.004. Epub 2017 Oct 31.

引用本文的文献

1
Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.司美替尼治疗成人1型神经纤维瘤病合并丛状神经纤维瘤
Pharmaceuticals (Basel). 2025 Jul 13;18(7):1039. doi: 10.3390/ph18071039.
2
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm.司美替尼治疗1型神经纤维瘤病和丛状神经纤维瘤儿科患者:SPRINT研究与自然病史对照臂的倾向评分分析
Neurooncol Adv. 2025 May 17;7(1):vdaf101. doi: 10.1093/noajnl/vdaf101. eCollection 2025 Jan-Dec.
3
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.司美替尼治疗1型神经纤维瘤病成人患者及有症状、无法手术的丛状神经纤维瘤的疗效和安全性(KOMET):一项多中心、国际、随机、安慰剂对照、平行、双盲、3期研究
Lancet. 2025 Jun 21;405(10496):2217-2230. doi: 10.1016/S0140-6736(25)00986-9. Epub 2025 Jun 2.
4
Treatment of Plexiform Neurofibromas : Current Perspectives on Surgery and Medical Treatment.丛状神经纤维瘤的治疗:手术及药物治疗的当前观点
J Korean Neurosurg Soc. 2025 May;68(3):252-260. doi: 10.3340/jkns.2025.0041. Epub 2025 Apr 30.
5
Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces the Incidence of Malignant Peripheral Nerve Sheath Tumour.对1型神经纤维瘤病患者进行密切随访可降低恶性外周神经鞘膜瘤的发病率。
Cancers (Basel). 2025 Apr 12;17(8):1306. doi: 10.3390/cancers17081306.
6
From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.从良性神经纤维瘤到恶性外周神经鞘瘤(MPNST):多种因素间的相互作用
Cell Oncol (Dordr). 2025 Apr 2. doi: 10.1007/s13402-025-01054-9.
7
Identification of the Determinants of Plexiform Neurofibroma Morbidity in Pediatric and Young Adult Neurofibromatosis Type 1 Patients: A Pilot Multivariate Approach.1型神经纤维瘤病患儿和年轻成人丛状神经纤维瘤发病因素的确定:一项探索性多变量研究方法
Cancers (Basel). 2025 Jan 2;17(1):123. doi: 10.3390/cancers17010123.
8
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.司美替尼治疗患有1型神经纤维瘤病(NF1)且无法手术切除的丛状神经纤维瘤成人患者:一项2期试验。
Nat Med. 2025 Jan;31(1):105-115. doi: 10.1038/s41591-024-03361-4. Epub 2025 Jan 6.
9
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.ReNeu:米哚妥林治疗有症状的1型神经纤维瘤病相关丛状神经纤维瘤成人和儿童的关键IIb期试验
J Clin Oncol. 2025 Feb 20;43(6):716-729. doi: 10.1200/JCO.24.01034. Epub 2024 Nov 8.
10
Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors.基于全身 MRI 的无初始肿瘤负荷且有新发生外周神经鞘瘤证据的儿童 NF1 患者的长期评估。
Orphanet J Rare Dis. 2024 Nov 4;19(1):412. doi: 10.1186/s13023-024-03420-6.

本文引用的文献

1
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.NF106:神经纤维瘤病临床试验联盟的一项 II 期试验,评估 MEK 抑制剂 Mirdametinib(PD-0325901)在 NF1 相关丛状神经纤维瘤的青少年和成人患者中的疗效。
J Clin Oncol. 2021 Mar 1;39(7):797-806. doi: 10.1200/JCO.20.02220. Epub 2021 Jan 28.
2
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.低突变负担和频繁缺失 CDKN2A/B 和 SMARCA2,但不缺失 PRC2,定义了良性神经纤维瘤病 1 相关非典型神经纤维瘤。
Neuro Oncol. 2019 Aug 5;21(8):981-992. doi: 10.1093/neuonc/noz028.
3
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.76 例不典型神经纤维瘤作为神经纤维瘤病 1 相关恶性外周神经鞘瘤前体的特征。
Neuro Oncol. 2018 May 18;20(6):818-825. doi: 10.1093/neuonc/noy013.
4
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.1型神经纤维瘤病患者非典型神经纤维瘤性肿瘤及其向恶性外周神经鞘瘤转化的组织病理学评估——共识综述
Hum Pathol. 2017 Sep;67:1-10. doi: 10.1016/j.humpath.2017.05.010. Epub 2017 May 24.
5
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼在1型神经纤维瘤病相关丛状神经纤维瘤中的活性
N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.
6
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.神经纤维瘤病 1 型患者的独特癌症相关性。
J Clin Oncol. 2016 Jun 10;34(17):1978-86. doi: 10.1200/JCO.2015.65.3576. Epub 2016 Feb 29.
7
Recommendations for imaging tumor response in neurofibromatosis clinical trials.神经纤维瘤病临床试验中肿瘤反应的影像学推荐建议。
Neurology. 2013 Nov 19;81(21 Suppl 1):S33-40. doi: 10.1212/01.wnl.0000435744.57038.af.
8
Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.1型神经纤维瘤病中,良性全身肿瘤体积是恶性外周神经鞘膜瘤的一个危险因素。
J Neurooncol. 2014 Jan;116(2):307-13. doi: 10.1007/s11060-013-1293-1. Epub 2013 Oct 29.
9
Optimizing biologically targeted clinical trials for neurofibromatosis.优化神经纤维瘤病的生物靶向临床试验。
Expert Opin Investig Drugs. 2013 Apr;22(4):443-62. doi: 10.1517/13543784.2013.772979. Epub 2013 Feb 21.
10
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.丛状神经纤维瘤的生长动力学:一项对 201 例神经纤维瘤病 1 型患者的回顾性队列研究。
Orphanet J Rare Dis. 2012 Oct 4;7:75. doi: 10.1186/1750-1172-7-75.